Plus Therapeutics, Inc. Files Amendment to S-1 Registration Statement

TL;DR

<b>Plus Therapeutics, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to comply with securities regulations.</b>

AI Summary

PLUS THERAPEUTICS, INC. (PSTV) filed a Amended IPO Registration (S-1/A) with the SEC on March 8, 2024. Plus Therapeutics, Inc. filed an amendment (S-1/A) to its registration statement on March 8, 2024. The filing is made under the Securities Act of 1933, with registration number 333-275712. The company's principal executive offices are located at 4200 Marathon Blvd., Suite 200, Austin, TX 78756. Andrew Sims is listed as the Chief Financial Officer and agent for service. The company was formerly known as Cytori Therapeutics, Inc. and Macropore Inc.

Why It Matters

For investors and stakeholders tracking PLUS THERAPEUTICS, INC., this filing contains several important signals. This amendment signifies the company's active engagement with the SEC for its securities offerings, suggesting progress in its capital-raising or compliance activities. The filing provides updated corporate information, including executive contacts and addresses, which is crucial for investors and regulators to maintain accurate records and communication channels.

Risk Assessment

Risk Level: low — PLUS THERAPEUTICS, INC. shows low risk based on this filing. The filing is a routine amendment to a registration statement, with no immediate financial or operational data presented that would indicate high risk.

Analyst Insight

Monitor future filings for details on the proposed securities offering and the company's financial health.

Key Numbers

• 333-275712 — SEC File Number (Registration number for the S-1 filing)
• 20240308 — Filing Date (Date the amendment was filed with the SEC)
• 1933 Act — SEC Act (Legislation under which the registration is filed)
• DE — State of Incorporation (Jurisdiction where the company is incorporated)

Key Players & Entities

• PLUS THERAPEUTICS, INC. (company) — Registrant name
• 333-275712 (registration_number) — SEC registration number
• 20240308 (date) — Filing date
• Andrew Sims (person) — Chief Financial Officer and agent for service
• 4200 Marathon Blvd., Suite 200, Austin, TX 78756 (address) — Principal executive offices
• CYTORI THERAPEUTICS, INC. (company) — Former company name
• MACROPORE INC (company) — Former company name
• Hogan Lovells US LLP (company) — Legal counsel

FAQ

Industry Context

The filing pertains to a company operating within the biotechnology or medical device sector, indicated by its SIC code and former names related to therapeutic and medical applications.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the purpose of the amendment and any proposed securities offering.
2. Track future SEC filings from Plus Therapeutics, Inc. for updates on their business and financial status.
3. Research the company's history, including its previous names and any significant events associated with them.

Key Dates

• 2024-03-08: Filing of S-1/A Amendment — Indicates ongoing regulatory compliance and potential securities offering activities.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating updates or additions to the initial registration statement.

Key Financial Figures

• $0 — d to the public in this offering, minus $0.001, and the exercise price of each pre
• $0.001 — rice of each pre-funded warrant will be $0.001 per share. For each pre-funded warrant
• $3.0 million — al cancer targets and we have an active $3.0 million award from U.S. National Institutes of

Filing Documents

• d845792ds1a.htm (S-1/A) — 341KB
• d845792dex231.htm (EX-23.1) — 2KB
• d845792dexfilingfees.htm (EX-FILING FEES) — 36KB
• g845792g01a00.jpg (GRAPHIC) — 43KB
• 0001193125-24-063694.txt (&nbsp;) — 435KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 14

USE OF PROCEEDS

USE OF PROCEEDS 15

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 19

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 25 PLAN OF DISTRIBUTION 29 LEGAL MATTERS 33 EXPERTS 33 WHERE YOU CAN FIND MORE INFORMATION 33 INCORPORATION BY REFERENCE 34 i Table of Contents ABOUT THIS PROSPECTUS You should read this prospectus and the related exhibits filed with the Securities and Exchange Commission (the SEC), together with the additional information described under the headings Where You Can Find More Information and Incorporation by Reference before making your investment decision. You should rely only on the information provided in this prospectus or in a prospectus supplement or any free writing prospectuses or amendments thereto. Neither we, nor the placement agent, have authorized anyone else to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus is accurate only as of the date hereof. Our business, financial condition, results of operations and prospects may have changed since that date. Neither we, nor the placement agent, are offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities as to distribution of the prospectus outside of the United States. Unless the context otherwise requires, references in this prospectus to Plus, the Company, we, us and our refer to Plus Therapeutics, Inc. Our logo and all product names are our common law trademarks. Solely for convenience, trademarks and tradenames referred to in this prospectus ma

View Full Filing

View this S-1/A filing on SEC EDGAR